OncoMatch/Clinical Trials/NCT06176027
Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
Is NCT06176027 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Azacytidine plus CAOLD regimen for relapsed peripheral t-cell lymphomas.
Treatment: Azacytidine plus CAOLD regimen — This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of azacytidine combined with CAOLD Regimen in the treatment of relapsed/refractory peripheral t-cell lymphomas.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Prior therapy
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L (≥ 1 x 10^9/L if bone marrow involvement by lymphoma); Platelet ≥ 75 x 10^9/L (≥ 50 x 10^9/L if BM involvement by lymphoma); Hemoglobin ≥ 8 g/dL
Meet the following lab criteria: Absolute Neutrophil Count (ANC) ≥ 1,5 x 10^9/L (≥ 1 x 10^9/L if bone marrow (BM) involvement by lymphoma); Platelet ≥ 75 x 10^9/L (≥ 50 x 10^9/L if BM involvement by lymphoma); Hemoglobin ≥ 8 g/dL.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06176027 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify